Of course, I pointed this out in a previous post where I stated: _________
Since HP-ß-CD has not previously been approved by the FDA as an active ingredient for a therapeutic treatment, it also will not be easily used off-label through a doctor’s prescription. Therefore, the incentives provided by the orphan drug designation to take HP-ß-CD to approval could be significant.